Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 22 (66.7%)

Trials by Status

terminated267%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_2

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

NCT01773785

terminatedphase_2

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

NCT01741155

completedphase_1

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

NCT00613691

Clinical Trials (3)

Showing 3 of 3 trials

NCT01773785Phase 2

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Terminated

NCT01741155Phase 2

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

Terminated

NCT00613691Phase 1

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3